Argonerica is a leading Microbiota Modulation Biotech brand that focuses on microbiota, microbiome, and microbial imbalance. Every human carries around 100 trillion microbial cells that live in our guts, lungs, and skin. These microbes, known as microbiota, are diverse and can have a significant impact on our health.

Scientists categorize different types of human microbiota based on their habitat, such as gut, vaginal, oral, lung, and skin microbiota. The activities and functions of human and microbial cells are controlled by their genome, and there are almost 100 times more microbial genes than human genes. Argonerica's patented technology allows for precise modification of microbiota, offering innovative topical treatment for various diseases and conditions associated with microbiota imbalance.

Recent advancements in biological sciences have led to a better understanding of the composition of microbiota and its relation to disease mechanisms, expanding the list of conditions associated with microbial imbalance. One of Argonerica's notable products is a non-antibiotic vaginal gel that targets pathogens associated with Bacterial Vaginosis without harming native Lactobacilli. This infection, although not life-threatening, is common among women of childbearing age and is linked to increased risks of HIV transmission and pre-term birth.

Traditional antibiotic treatments often lead to short-term symptom relief but contribute to the recurrence of the disease. Argonerica's gel aims to restore healthy microbiota balance and prevent disease recurrence by selectively targeting pathogens and promoting the growth of beneficial bacteria. Stay tuned for Argonerica's upcoming clinical trials in 2017, as they continue to revolutionize microbiota modification and develop groundbreaking treatments for a wide range of diseases and conditions associated with microbial imbalance